When the journey from obesity to cirrhosis takes an early start

Slides:



Advertisements
Similar presentations
THE PRESENCE OF HEPATIC STEATOSIS WHEN NO OTHER CAUSES FOR SECONDARY HEPATIC FAT ACCUMULATION NAFLD MAY PROGRESS TO CIRRHOSIS AND IS LIKELY AN IMPORTANT.
Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies  Gennaro D'Amico, Guadalupe Garcia-Tsao, Luigi.
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Ectopic fat and cardiometabolic and vascular risk
PNPLA3 gene in liver diseases
Treatment of NAFLD with diet, physical activity and exercise
Volume 61, Issue 6, Pages (December 2014)
Obesity, inflammation, and liver cancer
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Non-invasive diagnosis of non-alcoholic fatty liver disease
Immigration and viral hepatitis
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
Living donor liver transplantation: is the hype over?
Volume 149, Issue 2, Pages (August 2015)
David G. Bowen, Christopher M. Walker  Journal of Hepatology 
Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity  Samyah Shadid, Michael D Jensen  Clinical Gastroenterology.
Mesenchymal stromal cell therapy for liver diseases
Reply to: “DCD consensus and futility in liver transplantation”
Volume 69, Issue 2, Pages (August 2018)
Volume 44, Pages S19-S24 (January 2006)
Stephen A. Harrison, MD, FACP  Clinical Gastroenterology and Hepatology 
Volume 58, Issue 3, Pages (March 2013)
Reply to: “Low free T3 levels are related to early mortality in patients with decompensated cirrhosis and acute-on chronic liver failure”  Rakhi Maiwall,
Jordan J. Feld, Graham R. Foster  Journal of Hepatology 
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
European Association for the Study of the Liver  Journal of Hepatology 
Long-Term Outcomes of Nonalcoholic Fatty Liver Disease: From Nonalcoholic Steatohepatitis to Nonalcoholic Steatofibrosis  Zobair M. Younossi  Clinical.
Abstracts from Around the World
Amalia Gastaldelli, Giulio Marchesini  Journal of Hepatology 
Jennifer M. Croswell, Barnett S. Kramer  Journal of Hepatology 
Volume 61, Issue 3, Pages (September 2014)
Volume 54, Issue 5, Pages (May 2011)
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Cirrhosis and other liver disease in cystic fibrosis
Michael Charlton  Clinical Gastroenterology and Hepatology 
Genomic risk of hepatitis C-related hepatocellular carcinoma
Volume 69, Issue 4, Pages (October 2018)
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Volume 69, Issue 3, Pages (September 2018)
Coffee and tea breaks for liver health
The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver diseasePowell EE, Cooksley WGE, Hanson R, Searle J,
Hepatology may have problems with putative surrogate outcome measures
Volume 69, Issue 5, Pages (November 2018)
Current efforts and trends in the treatment of NASH
AGA technical review on nonalcoholic fatty liver disease
Paul C. Adams, James C. Barton  Journal of Hepatology 
NASH animal models: Are we there yet?
Immigration and viral hepatitis
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
Volume 64, Issue 6, Pages (June 2016)
Volume 63, Issue 1, Pages (July 2015)
Familial amyloidosis: Great progress for an orphan disease
Chronic hepatitis B in children and adolescents
Pathogenesis of cholestatic hepatitis C
Alcohol and cirrhosis: dose–response or threshold effect?
Sara Montagnese, Michele De Rui, Paolo Angeli, Piero Amodio 
This Month in AJKD American Journal of Kidney Diseases
The relationship between age and fat infiltration in liver and muscle
The metabolomic window into hepatobiliary disease
Genetics of hepatocellular carcinoma: The next generation
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Volume 135, Issue 6, Pages (December 2008)
Presentation transcript:

When the journey from obesity to cirrhosis takes an early start Vlad Ratziu, Giulio Marchesini  Journal of Hepatology  Volume 65, Issue 2, Pages 249-251 (August 2016) DOI: 10.1016/j.jhep.2016.05.021 Copyright © 2016 Terms and Conditions

Fig. 1 Descriptive diagram showing the interaction between genes and lifestyle in the development of excessive fat accumulation and liver-related outcomes in the course of life. For the sake of clarity, all cases are expected to start with normal body fat, but in a few cases in utero changes may also occur (babies born either small or large for gestational age), at high risk of future obesity or diabetes. Subjects may remain normal weight or minimally overweight throughout their life (green line), and will never intercept the level of liver disease (light orange area) or type 2 diabetes. Other individuals (brown line) will develop overweight or obesity during adulthood; they will intercept the level of liver disease and will develop NAFLD, at various stages of disease severity along the years (from pure fatty liver, to NASH, fibrosis, cirrhosis). The occurrence of type 2 diabetes will lower the threshold of their liver disease, as it lowers the threshold of liver-related death (dark orange area), in a time-dependent manner. In some cases, overweight or obesity might occur in early adulthood (red line), as in cases presented in the study by Hagström et al. In these cases, NASH is likely to occur early, and the threshold of liver-related death is reached at a relatively young age. Finally, in a few cases (blue line) overweight and obesity is present since childhood. In these cases, liver disease and liver-related death are anticipated further, with a remarkable reduction of life expectancy. Journal of Hepatology 2016 65, 249-251DOI: (10.1016/j.jhep.2016.05.021) Copyright © 2016 Terms and Conditions